KECK SENG TOWER 133 CECIL STREET #14-01 Singapore 069535
Company ProfileGero is a next generation AI drug discovery company designing therapies against complex diseases. The flagship project is a preclinical stage senolytic that demonstrates persistent rejuvenating effects in mammals.In its primary indication, the drug will be used against chemotherapy induced accelerated aging state in cancer patients. The novel drug should save cancer patients’ lives by helping them withstand multiple rounds of chemotherapy, otherwise withdrawn, and dramatically improve the quality of life of cancer patients and cancer survivors long after the treatment.Once the clinical safety and initial efficacy is established, the clinical trials could be expanded in a vast universe of senescence-associated diseases, including atherosclerosis, lung fibrosis, NAFLD and NASH, immunosenescence and others, including Parkinson’s and Alzheimer’s diseases. Gero’s early preclinical data suggests improvements in synaptic plasticity and hence the senolytic compound may be used to accelerate recovery from stroke or injury.Our drug discovery platform has a clear edge against complex diseases, especially those taking a long time to develop and lacking a strong association with a specific gene variant. Gero uses modern whole-exome and genome sequencing in conjunction with molecular interaction and specificity analysis to allow for efficient discovery of underlying biology of human disease and fast identification of relevant drug candidates.Gero is also providing health and mortality risk assessment models for life & health insurance, healthcare, and wellness industries.Gero R&D team led by Dr. Peter Fedichev applies methods from dynamics systems and physical kinetics to produce predictive models of aging process for anti-aging targets and aging biomarkers identification. Recent results include experimental therapies reducing biological age in mice, newly identified compounds extending life in other model animals, application of deep convolutional neural networks for identification of biomarkers of aging and frailty from wearable devices, and identification of genetic loci associated with human healthspan. The team has also introduced free iOS application Gero Healthspan for healthspan prediction from intraday physical activity of smartphone users.